There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sorrento Therapeutics (SRNE – Research Report), Aethlon Medical (AEMD – Research Report) and Evolus (EOLS – Research Report) with bullish sentiments.
Sorrento Therapeutics (SRNE)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sorrento Therapeutics, with a price target of $13.00. The company’s shares closed last Monday at $0.95, close to its 52-week low of $0.74.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.6% and a 27.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, MoonLake Immunotherapeutics, and Oncternal Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sorrento Therapeutics with a $9.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Aethlon Medical (AEMD)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aethlon Medical, with a price target of $9.00. The company’s shares closed last Monday at $0.63.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 19.8% and a 34.6% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Blue Water Vaccines, Inc., Finch Therapeutics Group, and Aridis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aethlon Medical with a $9.00 average price target.
Evolus (EOLS)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evolus today and set a price target of $15.00. The company’s shares closed last Monday at $9.82.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 15.5% and a 48.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Crinetics Pharmaceuticals.
Currently, the analyst consensus on Evolus is a Strong Buy with an average price target of $16.60, which is a 60.7% upside from current levels. In a report issued on January 18, Needham also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRNE: